1. Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22
- Author
-
Ryo Hatano, Nam H. Dang, Taketo Yamada, Chikao Morimoto, Hiroto Yamazaki, C. Wilson Xu, Yutaro Kaneko, Kei Ohnuma, and Toshihiro Okamoto
- Subjects
0301 basic medicine ,Mesothelioma ,Lung Neoplasms ,medicine.drug_class ,medicine.medical_treatment ,Dipeptidyl Peptidase 4 ,Pleural Neoplasms ,Cell ,Biophysics ,Mice, SCID ,Monoclonal antibody ,Antibodies, Monoclonal, Humanized ,Biochemistry ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Ubiquitin ,Cell Line, Tumor ,Histone H2A ,medicine ,Animals ,Humans ,RNA, Small Interfering ,Molecular Biology ,Cell Proliferation ,Gene knockdown ,Dipeptidyl-Peptidase IV Inhibitors ,Protease ,biology ,Chemistry ,Cell growth ,Gene Expression Profiling ,Mesothelioma, Malignant ,Cell Biology ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,Female ,Thiolester Hydrolases ,Ubiquitin Thiolesterase ,Neoplasm Transplantation - Abstract
Malignant pleural mesothelioma (MPM) is an aggressive malignancy arising from mesothelial lining of pleura. It is associated with a poor prognosis, partly due to the lack of a precise understanding of the molecular mechanisms associated with its malignant behavior. In the present study, we expanded on our previous studies on cell cycle control of MPM cells by targeting CD26 molecule with humanized anti-CD26 monoclonal antibody (HuCD26mAb), focusing particularly on ubiquitin-specific protease 22 (USP22). We showed that USP22 protein expression is detected in clinical specimens of MPM and that USP22 knockdown, as well as CD26 knockdown, significantly inhibits the growth and proliferation of MPM cells in vitro and in vivo. Moreover, depletion of both USP22 and CD26 suppresses MPM cell proliferation even more profoundly. Furthermore, expression levels of USP22 correlate with those of CD26. HuCD26mAb treatment induces a decrease in USP22 level through its interaction with the CD26 molecule, leading to increased levels of ubiquitinated histone H2A and p21. By demonstrating a CD26-related linkage with USP22 in MPM cell inhibition induced by HuCD26mAb, our present study hence characterizes USP22 as a novel target molecule while concurrently suggesting a new therapeutic strategy for MPM.
- Published
- 2018